Computationally Designed Stapled Peptides as Theranostics Targeting S100B in Cancer and Neurodegeneration | Research

The takeaway

Structure-guided computational design produced optimized stapled macrocyclic peptides that bind S100B(ββ) with high predicted affinity and can serve dual roles as both diagnostic imaging agents and therapeutic inhibitors.

Theranostic peptides
Same peptide molecule can both detect S100B levels (diagnosis) and block S100B disease-driving interactions (treatment) — precision medicine in one agent

What the researchers found

Computationally designed stapled macrocyclic peptides predicted to bind S100B(ββ) with high affinity. Modified with imaging agents for theranostic applications. Designed to disrupt S100B-partner protein interactions driving cancer and neurodegeneration.

Why it matters

S100B is implicated in melanoma, glioblastoma, Alzheimer's, and inflammatory conditions but has been "undruggable" with small molecules. Stapled peptides that both diagnose and treat could transform S100B-driven disease management.

The numbers in context

Multiple optimized stapled peptide analogs with predicted high-affinity S100B binding

How the study worked

Computational study. Comparative structural analysis of S100B-peptide complexes. Molecular dynamics simulations. Stapled peptide design and in silico mutagenesis optimization. Imaging agent conjugation for theranostic functionality.

Who was studied

N/A (in silico study)

What this study cannot tell us

Entirely computational — no experimental binding validation. Predicted affinities require in vitro confirmation. In vivo peptide delivery and imaging agent function not tested. Stapled peptide cell permeability assumed but not verified.

How to read the evidence

Low evidence grade: computational design study with no experimental validation. Predictions require in vitro and in vivo confirmation.

When this study was published

Published 2021. S100B as a therapeutic target continues to be explored with both peptide and small molecule approaches.

The bigger picture

Theranostic peptides — combining diagnosis and treatment in one molecule — represent a growing trend in precision medicine. Targeting S100B with such agents could enable personalized treatment decisions based on real-time biomarker monitoring.

Questions still open

Do the designed stapled peptides actually bind S100B with the predicted affinity?
Can the imaging agent-conjugated peptides detect S100B levels in vivo?
Would S100B inhibition slow cancer or neurodegeneration progression?

Common questions

What is S100B and why does it matter?

S100B is a protein that, when present at high levels, is linked to melanoma, brain cancer, Alzheimer's disease, and brain injury. It's already used as a blood biomarker for brain damage. Drugs that block it could potentially treat these conditions.

What is a theranostic?

A theranostic is a single agent that combines diagnosis and treatment. These designed peptides can both detect S100B (using attached imaging agents) and block its harmful interactions (through high-affinity binding) — enabling doctors to diagnose and treat simultaneously.

Read the original research

Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics.

Molecules (Basel, Switzerland), 26(3)

View on PubMed ↗Publisher’s paper ↗

Citation

Kannan, Srinivasaraghavan; Aronica, Pietro G A; Nguyen, Thanh Binh; Li, Jianguo; Verma, Chandra S. (2021). Computational Design of Macrocyclic Binders of S100B(ββ): Novel Peptide Theranostics.. Molecules (Basel, Switzerland), 26(3). https://doi.org/10.3390/molecules26030721